Emyria Welcomes Tattarang as Strategic Investor
Filed with ASX · · 5 pages · English
● Tattarang is one of Australia’s largest private investment groups and is owned by the Forrest family. ● Funds raised will be used to accelerate synthetic cannabinoid registration programs with the TGA and FDA, and advance Emyria’s novel MDMA-analogue development program with the University of Western Australia. ● For further information please visit tattarang.com Emyria Limited (ASX: EMD) (Emyri
Earlier from Emyria
- MDMA Analogue Development Milestone
- Emyria selected to join Palantirs Foundry Builders Program
- Novel MDMA Analogue Screening Program Advanced
- Emyria Expands Psychiatry Advisory for Psychedelics and MDMA
- MDMA-analogues Show Promise for Parkinsons Disease
Later from Emyria
- Emyria receives $1,162,000 R&D Tax Incentive Refund
- Positive initial MDMA-analogue screening results
- Positive animal data for Emyrias ultra-pure CBD capsule
- Pause in Trading
- Emyria adds wearables to psychedelic-assisted therapy trials
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria